MATTB provides assistance and training through outreach to industry. A: CDER's Division of Drug Information (DDI) serves as a focal point for public inquiries regarding human drug products.

CDER Director Patrizia Cavazzoni and CBER Director Peter Marks provided an update on the rare disease innovation hub in a new FDA Voices blog post. FDA’s Patrizia Cavazzoni, director, Center for Drug ...

The FDA proposed discontinuing the use of phenylephrine, an ingredient in common medications like Sudafed, because it 'is not effective' in treating cold and flu symptoms.

Drug Discov. 7, 107–109; 2008) — the FDA has been actively recruiting new employees, and CDER achieved a net gain of 396 staff in FY 2008 with 121 specifically working in the OND.

"It is the FDA's role to ensure that drugs are safe and effective," Dr. Patrizia Cavazzoni, who directs the FDA's Center for ...

Sudafed, Mucinex, Benadryl, Advil, Tylenol, Vicks, and Dimetapp. These popular brand names appear on oral decongestants that ...

and what specific improvements in speed and accuracy the FDA has observed so far? CDER, in collaboration with the Center for Biologics Evaluation and Research (CBER) and the Center for Devices and ...

The US Food and Drug Administration (FDA) has proposed an order to ban a popular ingredient in cold and flu medicines as it is seemingly not as effective as other methods. Oral phenylephrine is often ...

It will be co-led by Patrizia Cavazzoni, director of the FDA's Centre for Drugs Evaluation and Research (CDER), and Centre for Biologics Evaluation and Research (CBER) director Peter Marks.